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Background: HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. The
virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for
patients with HIV-2.
Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with inte-
grase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modal-
ities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed.
Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December
2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens.
After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in
89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and
126 cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13
treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3),
Y143C/G (3) and R263K (1).
Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individ-
uals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already
limited treatment options.
Introduction
HIV-2 was first described in 1986 in two patients from West Africa
presenting with AIDS.1 Current estimates indicate 1–2 million peo-
ple infected with HIV-2 worldwide, including dual HIV-1 plus HIV-2
coinfections.2 In contrast to the global spread of HIV-1, HIV-2 has
remained largely confined to some countries in West Africa where
it is endemic.3 In the EU, HIV-2 has been introduced by the large
immigration flow from Sub-Saharan countries.
A national registry of HIV-2 cases has existed in Spain since
1989, shortly after the first individuals with HIV-2 infection were
identified. They were three males of West African origin who had
recently arrived and were living in north Barcelona.4 Since then, a
total of 354 cases of HIV-2 infection have been reported to the
Spanish HIV-2 registry, of which 63% are in males. Whereas 72%
are Sub-Saharan Africans, 16% are native Spaniards. Although
most cases are found around the largest urban areas (Barcelona
and Madrid), two further foci of HIV-2 have been found in Galicia,
in the northwest and in Almeria, in the southeast coast of Spain,
most likely associated with sailors working in West Africa and the
recent arrival of illegal boats, respectively.5
ART for HIV-2 lags far behind HIV-1 therapeutics, owing to the
fact that the drugs have been designed using HIV-1 enzyme struc-
tures. Protein variability in HIV-2 explains the poor lack of binding
and inhibitory effect of some of these agents.6 In this regard,
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HIV-2 is non-susceptible to NNRTIs and fusion inhibitors.7,8
Moreover, several protease inhibitors show weak or no inhibitory
activity against HIV-2.7,9,10
All integrase strand transfer inhibitors (INSTIs) approved for the
treatment of HIV-1 are similarly active against HIV-2.11,12
Moreover, drug resistance mutations in patients with HIV-2 failing
on INSTIs tend to be selected at the same positions in both
viruses.7,13–16 However, the information available about the use of
INSTIs in HIV-2-infected individuals is scarce and limited to small
numbers of patients. In this nationwide observational study, we
analysed the clinical and virological outcome of all HIV-2-infected
individuals treated with INSTIs in Spain.
Patients and methods
The Spanish HIV-2 national register is a database that has collected informa-
tion from individuals diagnosed with HIV-2 infection across the country since
the registry began in 1989.5 In addition, a centralized laboratory repository of
stored clinical samples, including peripheral blood mononuclear cells and
plasma, exists for all HIV-2-infected individuals on regular follow-up, providing
virological information, including subtyping and drug resistance mutations.17
All HIV-2-infected individuals who had initiated ART with INSTI-based reg-
imens were identified. We retrospectively analysed demographics, treatment
modalities, laboratory values, quantitative plasma HIV-2 RNA and CD4 counts
as well as drug resistance mutations in patients failing ART. Treatment suc-
cess was defined as achievement of undetectable plasma viraemia (HIV-2
RNA ,50 copies/mL) at any time. In contrast, treatment failure was defined
as lack of achievement of undetectable viral load 12 weeks after beginning
therapy, or viral rebound after reaching undetectability.
Plasma HIV-2 RNA was measured using a non-commercial validated,
real-time PCR assay. The region amplified was the long terminal repeat
with primers and probes described elsewhere.18 The limit of detection was
HIV-2 RNA 50 copies/mL. Both HIV-2 groups A and B are reliably detected
with this assay.
Amplification of sequences within the polymerase region (protease, RT
and integrase) was attempted in plasma specimens. For HIV-2 RNA extrac-
tion, plasma was processed as indicated on the RNA extraction kit used
(Abbott sample preparation system RNA, Spain). Primers and conditions
have been previously described.13,19 The product was purified (QIAquick
PCR Purification Kit; QIAGEN, Germany) and finally sequenced using PCR
[BigDye Terminator v1.1, v3.1 5% Sequencing Buffer (Applied Biosystems,
UK) and BigDye Terminator v1.1 Cycle (Applied Biosystems, USA)]. Bulk
Sanger sequencing was carried out using the 3100-Avant Genetic Analyzer
(Applied Biosystems, USA). Sequences were analysed using SeqScape v2.5
using HIV-2 ROD as the reference strain.
Drug resistance-associated changes along with compensatory drug re-
sistance mutations were considered using the information available for
HIV-1 and HIV-2 at the Stanford HIV-1 drug resistance database,20 the
2011 International AIDS Society–USA panel mutation list21 and the HIV-2
EU-supporting resistance rules.22
Statistical analysis
All figures are recorded numerically as absolute values and percentages.
Comparisons between drug-naive and antiretroviral-experienced patients
were performed using v2 or Fisher’s exact tests. All statistical analyses were
performed using SPSS software version 20.0 (IBM Corp., Armonk, NY, USA).
Results
From 354 HIV-2-infected individuals recorded at the HIV-2
Spanish cohort up to December 2017, a total of 44 had been
treated with an INSTI, 18 being antiretroviral-naive and 26 having
had virological failure under another regimen. The main character-
istics of the study population are recorded in Table 1. Overall,
72.7% of these 44 individuals were male, with a median age of
43 years. More than 80% came from Sub-Saharan Africa and 70%
had acquired HIV-2 infection through heterosexual contacts.
Coinfection with HIV-1 had been demonstrated in five individuals.
There were no significant differences in demographics when com-
paring individuals who started INSTI as first-line therapy and those
who were treated with INSTI as a rescue intervention.
From the 18 drug-naive HIV-2 individuals who started treat-
ment with INSTI, nine received raltegravir, six elvitegravir and three
dolutegravir. Nucleoside analogues included as backbone were
mostly tenofovir with either emtricitabine or lamivudine. One pa-
tient also included darunavir/ritonavir in his initial treatment regi-
men (Table 2). Median baseline CD4 counts and HIV-2 viral load
were 264 cells/mm3 and 3.6 log copies/mL, respectively. However,
nearly half of individuals had undetectable plasma viraemia before
beginning treatment. After a median follow-up of 12 months, 16
(88.9%) individuals achieved and/or maintained undetectable
HIV-2 viraemia. The median CD4 gain was 82 cells/mm3.
A total of 26 individuals received INSTI as part of a rescue inter-
vention. They received raltegravir (19), dolutegravir (6) and elvite-
gravir (1). Moreover, all received two nucleoside analogues and 13
individuals included a boosted PI in the new regimen, with this
being darunavir/ritonavir in 10 of them (Table 2). The median CD4
count before beginning INSTI was 194 cells/mm3 and the median
plasma HIV-2 RNA was 3.7 log copies/mL in viraemic subjects. Of
note, roughly one-third of patients had undetectable HIV-2 RNA at
the time of shifting to INSTI, based on the clinical decision of the







No. 44 18 26
Median age at diagnosis,
years
43 (37–50) 44.5 (38–53) 43 (34–49)
Gender, n (%)
male 32 (72.7) 10 22
female 12 (27.3) 8 4
Risk group, n (%)
heterosexual 31 (70.5) 13 18
homosexual 1 (2.3) – 1
vertical 1 (2.3) – 1
unknown 11 (25) 5 6
Origin, n (%)
Africa 36 (81.8) 14 22
Spain 5 (11.4) 2 3
Portugal 2 (4.5) 1 1
Brazil 1 (2.3) 1 –
Year of diagnosis, n (%)
,2014 32 (72.7) 8 24
2014 12 (27.3) 10 2
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doctor in charge, considering poor CD4 response as the reason for
failing the prior regimen. A total of 17 (65.4%) individuals achieved
undetectable viraemia for a median of 13 months. However, four
baseline viraemic patients experienced relapse during further
follow-up. Overall, the median CD4 count gain in this population
was 126 cells/mm3.
Virological failure under INSTI-based therapy was recognized in
15 HIV-2-infected individuals, 2 being (11.1%) drug-naive and 13
(50%) treatment-experienced. Of them, only four had achieved
undetectable viral load at some point during therapy, experiencing
relapse shortly after. The remaining 11 patients did not reach un-
detectable viraemia at any timepoint. The mean time between ini-
tiation of INSTI-based therapy and genotypic analysis at failure
was 42 weeks (range 16–88).
A total of 12 individuals developed INSTI-associated resist-
ance mutations N155H (5), Q148H/R (3), Y143C/G (3) and R263K
(1). All but one developed other compensatory changes
(Table 3). For the RT viral region, seven individuals developed
M184V, six K65R and one Q151M. Combinations of these muta-
tions were seen in three cases, one being K65R!Q151M and
two K65R!M184V. In addition, substitutions were recognized
at the protease in 10 patients, as follows: I50V (3); I54L/M (6);
I82F/L (5); I84V (3); and L90M (3). In eight of them, these
changes reflected mutations persisting after failing previously
on PI-based therapies.
Discussion
The treatment of HIV-2-infected individuals generally follows the
rules of HIV-1 with a few special considerations.23–25 However, to
date no information drawn from randomized controlled trials
guides the timing for ART initiation in patients with HIV-2, and
there are some conflicting opinions.11 Thus, the optimal treatment
strategy for HIV-2 infection remains unclear. Current guidelines for
HIV-2-infected individuals are based on retrospective cohort stud-
ies, small case series, individual case reports, in vitro data and ex-
trapolation from studies conducted in patients with HIV-1.6,25
All INSTIs approved to date for HIV-1 exhibit potent activity
against HIV-2.26–28 Two recent clinical trials conducted in France
and Senegal, respectively, evaluated the efficacy and safety of ral-
tegravir and elvitegravir as first-line ART in HIV-2-infected individu-
als. The first study, conducted by Matheron et al.,29 assessed the
combination of raltegravir/emtricitabine/tenofovir in 30 HIV-2
infected patients. In terms of virological response, 27 of 28 partici-
pants who completed the 48 week follow-up achieved,40 copies/mL
with a median CD4 gain of!87 cells/mm3. However, only 40% of
Table 2. Main clinical characteristics of patients with HIV-2 treated with integrase inhibitors
Characteristic Antiretroviral-naive Treatment-experienced
No. 18 26
Baseline CD4 counts, cells/mm3, median (IQR) 264 (134–604) 194 (52–421)
Plasma HIV-2 RNA
baseline plasma HIV-2 RNA undetectable, n (%) 8 (44.4%) 10 (38.5%)
VL in viraemic patients, log copies/mL, median (IQR) 3.6 (2.6–4.2) 3.7 (2.7–4.4)




Integrase inhibitors, n (%)
raltegravir 9 (50%) 19 (73.1%)
elvitegravir 6 (33.3%) 1 (3.8%)
dolutegravir 3 (16.7%) 6 (23.1%)
Protease inhibitors, n (%)
darunavir/ritonavira 1 (5.6%) 10 (38.5%)
others 0 3b (11.5%)
Nucleoside analogues, n (%)
tenofovir alafenamide! emtricitabine 4 (22.2%) 1 (3.8%)
tenofovir disoproxil fumarate! lamivudine or emtricitabine 11 (61.1%) 17 (65.4%)
abacavir! lamivudine 3 (16.7%) 3 (11.5%)
none 0 5
Patients with undetectable VL at any time during follow-up, n (%) 16 (88.9%) 17c (65.4%)
Time with undetectable VL, months, median (IQR) 12 (6–29) 13 (0–27.5)
Gain in CD4 counts, cells/mm3, median (IQR) 82 (13–272) 126 (48–200)
Treatment failure on integrase inhibitor, n (%) 2 (11.1%) 13 (50%)
VL, viral load.
a600 mg/100 mg twice daily.
bOne lopinavir/ritonavir; one tipranavir/ritonavir; one saquinavir/ritonavir.
cFour individuals achieved undetectable viraemia after beginning integrase inhibitor therapy but VL rebounded during follow-up.
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participants were considered to have had a successful response
to the predefined primary endpoint, which was a CD4 gain
.100 cells/mm3. In the second study, conducted by the
University of Washington-Dakar HIV-2 study group,30 a total of
30 HIV-2 participants initiated elvitegravir/cobicistat/emtricita-
bine and tenofovir. Overall, 93.3% of individuals had viral sup-
pression at week 48. The median CD4 increase was of!161 cells/
mm3.30 Overall, our results in treatment-naive individuals are in
agreement with major findings in these two studies. Most of our
patients (16 of 18; 88.9%) achieved viral suppression with a me-
dian CD4 gain at 1 year of!81 cells/mm3.
Altogether, treatment outcomes in HIV-2 differ from those
seen in HIV-1. For instance, a subset of patients in all three HIV-2
studies (roughly half in our series) had undetectable viraemia at
baseline, which almost never occurs in HIV-1. Second, CD4 gains in
HIV-2 were relatively modest compared with what is generally
seen in treated HIV-1-infected individuals. Lastly, the recognition
of frequent selection of drug resistance mutations in HIV-2 individ-
uals that failed virologically, despite low viral load values, must be
a matter concern. It supports the overall lower barrier to resistance
in HIV-2 compared with HIV-1 for currently available
antiretrovirals.
The use of INSTI as part of rescue interventions for HIV-2-
infected individuals experiencing treatment failure has been
examined in prior studies,31–33 including some from our group.19,34
Benefits are generally seen in both viral suppression and immune
recovery, as it was noticed in the present study. However, only half
of our 26 HIV-2 pretreated patients that began INSTI achieved and
maintained undetectable viraemia for a median of 13 months.
While four regained undetectability and rebounded thereafter, the
rest failed to achieve undetectable viraemia under INSTI
treatment. Moreover, all but three failures selected INSTI
resistance-associated mutations.
Regarding resistance patterns at the integrase gene in patients
that failed on INSTI, the following mutations were found in 12
patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). All
but one developed other compensatory INSTI mutations including
E92Q (4), T97A (2), G140A/S (3) and A153G/S (4). Mutation T97A
has been recently reported as a minority resistant variant in one
naive HIV-2-infected patient.35 By itself, this mutation is not known
to confer INSTI resistance, but may reduce susceptibility when pre-
sent in combination with others.
To our knowledge, this is the first report of R236K plus E92G as a
potential mechanism of loss of susceptibility to dolutegravir in
HIV-2. The virus was a subtype B variant. In HIV-1 infection, the
R263K mutation was originally reported in one individual who
failed first-line dolutegravir-based therapy36 and another new
case has been recently reported.37 Further in vitro studies using
R263K mutants have shown that it confers a moderate increase in
phenotypic resistance to INSTIs along with a drastic reduction in
viral replicative capacity.38 E92G is a rare non-polymorphic change
occasionally selected in patients receiving elvitegravir.17
Hypothetically, the combination of R263K and E92G could account
for virological failure in our patient.
A recent report has described a new resistance pattern for
patients with HIV-2 failing raltegravir. The pattern consists of a five
amino acid insertion in the C-terminal region of the integrase
gene.39 We have not observed this insertion in our patients failing
raltegravir. However, this pattern has been identified in another
patient failing dolutegravir after prior failure with raltegravir (data
not shown). Interestingly, this resistance pattern has been previ-
ously described in animal models treated with long-acting
















N_1 M (13) Equatorial Guinea B ABC!3TC! RAL no N155H/E92Q – M184V
N_2 M (40) Guinea Bissau A TDF! FTC!DRV/r! RAL no N155H/E92Q/T97A I54M/I82F/L90M M184V
F_1 M (63) Guinea Bissau unknown TDF! FTC!DTG no – – –
F_2 M (17) Cabo Verde A ddI!MVC!DRV/r! RAL no N155H/A153G I54M/I82F/L90M K65R/Q151M
F_3 M (51) Mali A TDF! FTC!ATV/r! RAL yes (14) N155H/A153G I84V/L90M –
F_4 M (58) Spain B TDF! TPV/r! RAL no N155H/A153G I54L/I82L M184V
F_5 M (49) Senegal A TDF! FTC!DRV/r! RAL yes (34) – – M184V
F_6 F (40) Senegal A TDF! FTC! RAL no – – –
F_7 M (40) Guinea Bissau A TDF!DTG!DRV/r no Q148H/G140S I50V K65R
F_8 F (38) Portugal A TDF! FTC! RAL yes (11) Q148R/G140A I82L/I84V –
F_9 M (48) Senegal A DRV/r!MVC! RAL no Q148R/G140S I50V M184V
F_10 M (53) Senegal B DRV/c!DTG yes (16) R263K/E92G I50V/I54L K65R
F_11 M (52) Spain B TDF!DRV/r! RAL no Y143C I54M/I84V K65R
F_12 M (47) Africa A ZDV!3TC! RAL no Y143C/E92Q I54M/I82F K65R/M184V
F_13 M (37) Guinea Bissau A TDF! FTC! RAL no Y143G/T97A/A153S – K65R/M184V
M, male; F, female; VL, viral load; ABC, abacavir; 3TC, lamivudine; ZDV, zidovudine; ddI, didanosine; FTC, emtricitabine; TDF, tenofovir; RAL, raltegravir;
DTG, dolutegravir; DRV, darunavir; ATV, atazanavir; LPV, lopinavir; TPV, tipranavir; r, ritonavir; c, cobicistat; MVC, maraviroc.
aN, patient was treatment-naive; F, patient was treatment-experienced.
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cabotegravir and resulted in high-level resistance to cabotegravir,
dolutegravir, elvitegravir and raltegravir.40
Several limitations of our study should be acknowledged, the
most relevant being the lack of consideration of drug compliance.
This information was reliable for only a subset of patients. For in-
stance, the two native Spaniards who failed treatment were poorly
adherent to their medication. However, for most of the rest, who
were African immigrants, drug compliance could not be assessed
reliably owing to difficulties with language and regular attendance
at outpatient appointments. A second limitation of our study is
that HIV-1 was not considered in any way for the subset of
patients with dual HIV-1 plus HIV-2 infection. However, all of them
had undetectable HIV-2 RNA at the end of follow-up. Finally, we
used the Sanger sequence instead of next-generation sequencing
for the analysis of drug resistance mutations. We identified three
failing patients without drug resistance to integrase inhibitors, and
minority changes might have been present.
Our study highlights several aspects of HIV-2 ART. First, treat-
ment with INSTIs seems to be safe and effective in HIV-2-infected
individuals, particularly in the subset who is drug-naive. In this re-
gard, our findings in real-world patients confirm those obtained in
recent controlled studies. Secondly, the proportion of patients with
HIV-2 developing resistance mutations to INSTIs after virological
failure seems to be high in comparison with the experience with
HIV-1, suggesting that the resistance barrier to INSTIs in HIV-2
may be lower. Thirdly, integrase resistance profiles often involved
a large number of changes, leading to uncertainty about cross-
resistance, even for the most recent INSTIs such as bictegravir and
cabotegravir.
Given that the clinical management of HIV-2-infected patients
should follow the rules of HIV-1 infection, early diagnosis and
treatment initiation is recommended. However, owing to the lim-
ited therapeutic armamentarium for HIV-2 compared with HIV-1,
this population must be closely followed-up, bearing in mind that
rescue interventions may be challenging.
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